Every 10 minutes, someone in the U.S. is added to an organ transplant waitlist. Thirteen people die each day waiting for a donor that may never come. Only about 10 percent of global organ demand is currently met.

Those numbers have barely moved in decades. Not because the problem is ignored, but because the biology is genuinely hard.

Eric Bennett thinks the field has been solving the wrong subproblem. The organ shortage isn't primarily a donor matching problem or an immune suppression problem. It's a manufacturing problem. And manufacturing problems are solvable.

Bennett is a serial entrepreneur and biomedical engineer who spent years at the intersection of hardware and human biology.

Before founding Frontier Bio, he served as CTO at Aether, where he developed advanced low-cost bioprinters. His scientific background spans brain-computer interfacing, optogenetics, microfluidics, DNA assembly, and bioprinting. Earlier work focused on using optogenetics and brain-computer interfaces to study and reduce neural disorders.

That trajectory matters. Bennett isn't approaching tissue engineering from a pure biology background. He's approaching it as someone who builds things, someone who has spent his career asking what happens when you apply precision hardware to biological problems.

The answer Frontier Bio is building toward: living blood vessels that replace synthetic grafts, integrate seamlessly with the patient's own body, and eventually become the vascular infrastructure for fully engineered organs.

Q: What originally drew you to tissue engineering, and what convinced you that Frontier Bio could meaningfully change healthcare?

Eric: Working on brain-computer interfaces first introduced me to advanced 3D printing for device engineering. That experience with additive manufacturing opened the door to applying similar techniques to biology.

I wanted to work on something that sounded like science fiction but could actually become reality with enough hard work. The scale of potential impact made it clear: we have a chance to drastically reduce reliance on animal testing and eventually eliminate the organ transplant waitlist entirely.

Q: Only about 10 percent of global organ demand is currently met. Why has this problem remained unsolved for so long?

Eric: The core issue is a severe donor shortage. Even when a donor is found, the immune system creates another barrier. Strict biological matching is required to prevent rejection, and the body can still reject an organ years later.

Tissue engineering offers a real alternative, but the field has historically struggled to replicate the complexity of human biology. To actually solve the problem, you have to rebuild from the ground up. That's why we're starting with blood vessels.

Q: Why is vascularization the foundation for engineering more complex organs?

Eric: Growing cells isn't the hard part. Keeping them alive is.

You can grow heart or liver cells in a dish, but the moment you try to build something thick and three-dimensional, the cells at the center starve. Oxygen and nutrients can't reach them without a blood supply.

Blood vessels are the infrastructure that makes everything else possible. Mastering vascularization is how you build a path toward transplantable kidneys, lungs, and hearts. It's not a stepping stone. It's the core technical problem.

Q: Synthetic vascular grafts already exist. What makes your living vascular graft fundamentally different?

Eric: Current synthetic grafts are made from permanent plastics like Teflon or Dacron. The body recognizes them as foreign and fights them. That leads to chronic inflammation, infection, and clotting. In some applications, these grafts fail at rates up to 65 percent within two years.

Frontier Bio uses a bioresorbable scaffold instead. Once implanted, it provides immediate structure and blood flow. Over time, it breaks down safely and is replaced by the patient's own cells. The result is a living blood vessel the body accepts as its own. There's no long-term rejection risk because there's nothing foreign left.

Q: Your approach seeds a patient's own stem cells onto the scaffold at the bedside. Why is that model superior to centralized manufacturing?

Eric: Other companies grow cells on scaffolds in external labs. That takes weeks, costs a significant amount, and introduces logistical complexity at every step.

Our approach skips all of that. By seeding the patient's stem cells directly onto the scaffold during the procedure, we use the patient's body as the bioreactor. The immune rejection risk disappears.

The cost structure is fundamentally different. And outcomes improve because the biology doing the work is already matched to the patient.

Q: The FDA and NIH are moving away from requiring animal testing. How does that shift affect Frontier Bio?

Eric: The FDA Modernization Act removes the mandate for animal testing in drug development. That's a significant catalyst for us. Animal models frequently fail to predict how humans will respond to drugs, which is why so many compounds fail in late-stage clinical trials.

Our 3D bioprinted human tissue models offer a human-relevant alternative. Companies can test faster and more accurately. The regulatory shift accelerates adoption of those models, which drives near-term revenue and validates the same biomanufacturing platform we'll use for full organ engineering.

Q: You've already commercialized human tissue models. How does that strengthen your long-term organ engineering work?

Eric: Building transplantable organs takes time and capital. The tissue model business generates non-dilutive revenue that helps fund that long-term R&D.

More importantly, every tissue model we deploy in the real world proves that our engineered structures function and survive. It's continuous validation. It de-risks our pipeline and builds credibility with partners, investors, and regulators step by step, rather than asking anyone to take a leap of faith.

Q: Cardiovascular disease is the leading cause of death worldwide. What's your first clinical target, and why?

Eric: Our first targets are patients with severe Peripheral Artery Disease and patients who need reliable hemodialysis access. Both groups face devastating outcomes when synthetic grafts fail. PAD patients often lose limbs. Dialysis patients endure repeated revision surgeries when their grafts clot.

We chose peripheral applications first because the surgical environment is accessible and the clinical need is acute. Proving safety and efficacy here creates the foundation for coronary applications later.

Q: What are the biggest execution risks over the next three years?

Eric: The primary risks are clinical and regulatory. Getting through First-in-Human trials and proving long-term graft patency are the hardest hurdles. We address this through early regulatory engagement and rigorous preclinical data.

Manufacturing is the second challenge. Scaling production of bioresorbable scaffolds while maintaining quality control is not simple.

The third is market adoption. Surgeons are used to pulling synthetic tubes off the shelf. We have to demonstrate that our bedside seeding approach delivers better outcomes and fits into existing workflows, not disrupts them.

Q: Ten years from now, what has to be true for Frontier Bio to say it reshaped the future of engineered tissue?

Eric: Three things.

First, living vascular grafts become the standard of care for PAD and hemodialysis access. Permanent synthetic plastics become the outdated option.

Second, bedside biomanufacturing is widely adopted. The patient's own biology, used at the point of care, replaces slow and expensive centralized lab culturing.

Third, we move up the complexity ladder. We use mastery of vascularization to demonstrate functional, biofabricated organs and build the infrastructure to end organ waitlists at scale.

Those three shifts together would mean we actually did what we set out to do.